Amicus Therapeutics, Inc. FOLD
At closeApr 27, 2026, 4:00 PM EDT
After hours · Apr 27, 4:00 PM ET
52-week range unavailable
- YTD
- +1.76%
- 1 year
- +97.14%
- Market cap
- 4.55B
- Profit margin
- -1.07%
- YTD return
- +1.76%
- 1-year return
- +97.14%
- Open
- 14.49
- Previous close
- 14.49
- Day's range
- 14.49 – 14.49
- Earnings date
- May 7, 2026
Key statistics
- Enterprise value
- 4.82B
- PEG ratio
- 8.04
- Price / sales
- 0.00
- Price / book
- 16.33
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Total cash
- 0
- Total debt
- 2
- Return on equity
- -2.30%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
- Strong buy8
- Buy1
- Hold3
- Sell0
- Strong sell0
Next earnings
May 7, 2026
Expected May 7, 2026. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 7, 2026 | Mar 31, 2026 | 0.04667 | — | — | — |
| Feb 20, 2026 | Dec 31, 2025 | 0.07143 | 0.01 | -0.06 | -86.00% |
| Nov 4, 2025 | Sep 30, 2025 | 0.03857 | 0.06 | +0.02 | +55.56% |
| Jul 31, 2025 | Jun 30, 2025 | -0.05 | -0.08 | -0.03 | -60.00% |
| May 1, 2025 | Mar 31, 2025 | 0.01 | -0.07 | -0.08 | -800.00% |
| Feb 19, 2025 | Dec 31, 2024 | 0.02 | 0.09 | +0.07 | +350.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 22, 2026 | Jefferies | down | Buy | Hold |
| Dec 29, 2025 | Leerink Partners | down | Outperform | Market Perform |
| Dec 22, 2025 | Citigroup | down | Buy | Neutral |
| Dec 19, 2025 | Needham | down | Buy | Hold |
| Dec 19, 2025 | Cantor Fitzgerald | down | Overweight | Neutral |
| Dec 17, 2025 | Citigroup | init | — | Buy |
About Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data. The company's pipeline also includes several investigational therapies: AT-GAA, an innovative treatment strategy for Pompe disease; various enzyme replacement therapies aimed at Pompe diseases; and AT-GTX-502, an AAV serotype gene therapy for CLN3. The latter is currently undergoing Phase 1/2 clinical studies to evaluate the safety and efficacy of a single intrathecal administration in patients with CLN3. Additionally, Amicus is exploring therapeutic approaches related to CDKL5, a gene on the X-chromosome that encodes a protein essential for regulating proper brain development. Amicus maintains strategic collaborations and licensing arrangements with prominent entities such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. The company was founded in 2002 and is based in Philadelphia, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 499
- Website
- amicusrx.com
News
This Hedge Fund Portfolio Shrinks 17% as Billionaire Bets Big on Gold 
Praxis Precision Medicines To Rally More Than 213%? Here Are 8 Top Analyst Forecasts For Monday 
Nasdaq Surges Over 1%; Lamb Weston Shares Decline Following Q2 Results 
Carnival Posts Strong Q4 Earnings, Joins Amicus Therapeutics, Biomarin Pharmaceutical And Other Big Stocks Moving Higher On Friday 
12 Health Care Stocks Moving In Friday's Intraday Session 
Earnings Scheduled For November 4, 2025 
Earnings Scheduled For July 31, 2025 
12 Health Care Stocks Moving In Thursday's Pre-Market Session 
Earnings Scheduled For May 1, 2025 
Earnings Scheduled For February 19, 2025
Your note
Sign in to keep a note on FOLD — it syncs with the Stock Master app.